Галидесивир (Galidesivir; BCX4430)
Международное непатентованное наименование
Галидесивир (Galidesivir; BCX4430)
Торговое наименование
-
Производитель, страна
BioCryst Pharmaceuticals, USA
Механизм действия
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Публикации COVID-19
Abdo A Elfiky. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir Against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp): A Molecular Docking Study. Life Sci. 2020 Mar 25;117592. doi: 10.1016/j.lfs.2020.117592.
Клинические исследования
1.
Название протокола
A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19
Дата начала и окончания КИ
April 9, 2020 - May 31, 2021
Название организации, проводящей КИ
BioCryst Pharmaceuticals
Страны
Brazil
Фаза
Ib
Кол-во пациентов
66